| Indicators | Browse All

Sonoma Pharmaceuticals, Inc. (SNOA)

Healthcare | Drug Manufacturers - Specialty & Generic | Boulder, United States | NasdaqCM
1.18 USD -0.05 (-4.065%) ⇩ (Oct. 13, 2026, 4 p.m. EDT)

Short-term:★★☆☆☆Long-term:★⯪☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 2:23 a.m. EDT

The immediate outlook remains heavily weighted toward caution due to a severe deterioration in the company's financial health. While the stock recently rallied on operational updates regarding retail launches, the underlying business is bleeding cash aggressively, with operating cash flow and free cash flow both deeply negative. This cash burn is being funded by dilutive capital raises, evidenced by recent public offerings and lock-up expirations, which suggests management is struggling to bridge the gap without selling equity. The balance sheet is fragile, with debt significantly outpacing equity, creating a precarious situation for a speculative biotech play. Although the price has recovered somewhat from multi-year lows, the lack of profitability and reliance on external financing make a near-term bullish case tenuous at best, leaning more toward a wait-and-see approach for any potential catalysts.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.131688
AutoETS0.134474
AutoTheta0.134585
MSTL0.134875

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 40%
H-stat 0.59
Ljung-Box p 0.000
Jarque-Bera p 0.000
Excess Kurtosis 1.95
Attribute Value
Sector Healthcare
Debt to Equity Ratio 11.207
Revenue per Share 9.807
Market Cap 5,650,341
Forward P/E -2.11
Beta 1.30
Profit Margins -10.33%
Website https://sonomapharma.com

Info Dump

Attribute Value
52 Week Change -0.6977887
Address1 5,445 Conestoga Court
Address2 Suite 150
All Time High 72,324.0
All Time Low 0.85
Ask 1.62
Ask Size 2
Average Daily Volume10 Day 42,900
Average Daily Volume3 Month 106,487
Average Volume 106,487
Average Volume10Days 42,900
Beta 1.304
Bid 0.936
Bid Size 2
Book Value 1.378
City Boulder
Compensation As Of Epoch Date 1,798,675,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.18
Current Ratio 2.987
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 1.25
Day Low 1.17
Debt To Equity 11.207
Display Name Sonoma Pharmaceuticals
Dividend Date 1,560,988,800
Dividend Yield 0.0
Earnings Timestamp End 1,754,942,400
Earnings Timestamp Start 1,754,510,400
Ebitda -1,271,000
Ebitda Margins -0.057979997
Enterprise To Ebitda -0.827
Enterprise To Revenue 0.048
Enterprise Value 1,051,341
Eps Forward -0.56
Eps Trailing Twelve Months -1.22
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.2836
Fifty Day Average Change -0.103600025
Fifty Day Average Change Percent -0.08071052
Fifty Two Week Change Percent -69.77887
Fifty Two Week High 4.25
Fifty Two Week High Change -3.0700002
Fifty Two Week High Change Percent -0.722353
Fifty Two Week Low 0.85
Fifty Two Week Low Change 0.32999992
Fifty Two Week Low Change Percent 0.38823518
Fifty Two Week Range 0.85 - 4.25
Financial Currency USD
First Trade Date Milliseconds 1,169,735,400,000
Float Shares 4,768,409
Forward Eps -0.56
Forward P E -2.1071427
Free Cashflow -1,469,750
Full Exchange Name NasdaqCM
Full Time Employees 10
Fullday Change -0.05000007
Fullday Change Percent -4.0650463
Fullday Price 1.18
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.38904998
Gross Profits 8,528,000
Has Pre Post Market Data 1
Held Percent Insiders 0.00416
Held Percent Institutions 0.023139998
Implied Shares Outstanding 4,788,425
Industry Drug Manufacturers - Specialty & Generic
Industry Disp Drug Manufacturers - Specialty & Generic
Industry Key drug-manufacturers-specialty-generic
Ir Website http://ir.oculusis.com/
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,774,915,200
Last Split Date 1,724,976,000
Last Split Factor 1:20
Long Business Summary Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Long Name Sonoma Pharmaceuticals, Inc.
Market us_market
Market Cap 5,650,341
Market State POST
Max Age 86,400
Message Board Id finmb_8652169
Most Recent Quarter 1,782,777,600
Net Income To Common -2,264,000
Next Fiscal Year End 1,806,451,200
Non Diluted Market Cap 6,009,473
Open 1.25
Operating Cashflow -2,567,000
Operating Margins -0.00624
Payout Ratio 0.0
Peg Ratio 1.08
Phone 800 759 9305
Previous Close 1.23
Price Hint 4
Price To Book 0.85631347
Price To Sales Trailing12 Months 0.25777104
Profit Margins -0.10328
Quick Ratio 1.564
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.05000007
Regular Market Change Percent -4.0650463
Regular Market Day High 1.25
Regular Market Day Low 1.17
Regular Market Day Range 1.17 - 1.25
Regular Market Open 1.25
Regular Market Previous Close 1.23
Regular Market Price 1.18
Regular Market Time 1,791,921,600
Regular Market Volume 47,720
Return On Assets -0.053740002
Return On Equity -0.42516
Revenue Growth 0.596
Revenue Per Share 9.807
Sand P52 Week Change 0.17502642
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 4,788,425
Shares Percent Shares Out 0.0344
Shares Short 164,505
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 182,313
Short Name Sonoma Pharmaceuticals, Inc.
Short Percent Of Float 0.0345
Short Ratio 3.13
Source Interval 15
State CO
Symbol SNOA
Total Cash 5,338,000
Total Cash Per Share 1.115
Total Debt 739,000
Total Revenue 21,920,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.22
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.87695
Two Hundred Day Average Change -0.6969501
Two Hundred Day Average Change Percent -0.37132052
Type Disp Equity
Volume 47,720
Website https://sonomapharma.com
Zip 80,301